TABLE 1.
Patients' characteristics
| Variables | Patients (n = 118) |
|---|---|
| Age, yeas | 66 (60–75) |
| Gender | |
| Female | 37 (31.4%) |
| Male | 81 (68.6%) |
| Body mass index, kg/m2 | 22.5 (20.3–24.4) |
| Primary tumor location | |
| Ascending colon | 19 (16.1%) |
| Transverse colon | 12 (10.2%) |
| Descending colon | 10 (8.5%) |
| Sigmoid colon | 36 (30.5%) |
| Rectum | 41 (34.7%) |
| T factor | |
| T1 | 2 (1.7%) |
| T2 | 5 (4.2%) |
| T3 | 72 (61.0%) |
| T4 | 39 (33.1%) |
| Lymph node metastases | |
| Yes | 74 (62.7%) |
| No | 44 (37.3%) |
| Timing of tumor | |
| Synchronous | 74 (62.7%) |
| Metachronous | 44 (37.3%) |
| Novel H classification | |
| nH1 | 44 (37.3%) |
| nH2 | 6 (5.1%) |
| nH3 | 68 (57.6%) |
| Tumor size, mm | 49 (19–45) |
| Resectability | |
| Resectable | 104 (88.1%) |
| Borderline resectable | 12 (10.2%) |
| Unresectable | 2 (1.7%) |
| Neoadjuvant chemotherapy | |
| Yes | 41 (34.7%) |
| No | 77 (65.3%) |
| Serum CEA, ng/mL | 11.1 (4.7–38.7) |
| CXI | |
| High | 25 (21.2%) |
| Low | 93 (78.8%) |
| Serum CEA, ng/mL | 11.1 (4.7–38.7) |
Abbreviations: CEA, carcinoembryonic antigen; CXI, cachexia index.